CP-654577

reduces the levels of the activated form of mitogen-activated protein kinase, increases the levels of cyclin-dependent kinase inhibitor p27(kip1) and reduces expression of cyclins D and E; structure in first source

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Barbacci, E Gabriella: 1 article (08/2003)
2.	Boscoe, Brian P: 1 article (08/2003)
3.	Cox, Eric D: 1 article (08/2003)
4.	Emerson, Erling: 1 article (08/2003)
5.	Iwata, Kenneth K: 1 article (08/2003)
6.	Jani, Jitesh P: 1 article (08/2003)
7.	Kath, John C: 1 article (08/2003)
8.	Liu, Zhengyu: 1 article (08/2003)
9.	Miller, Penny E: 1 article (08/2003)
10.	Moyer, James D: 1 article (08/2003)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2003 - "CP-654577 warrants further evaluation in tumors with high expression of p185(erbB2) and may differ from selective EGFr inhibitors or nonselective dual EGFr/erbB2 inhibitors in efficacy and therapeutic index." 08/01/2003 - "CP-654577 produced a dose-dependent reduction of p185(erbB2) autophosphorylation and inhibited the growth of these tumors. "
2.	Breast Neoplasms (Breast Cancer) 08/01/2003 - "The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells." 08/01/2003 - "Treatment of SKBr3 human breast cancer cells with CP-654577 reduces the levels of the activated form of mitogen-activated protein kinase, increases the levels of cyclin-dependent kinase inhibitor p27(kip1) and reduces expression of cyclins D and E. "

Related Drugs and Biologics

1.	Cyclin-Dependent Kinase Inhibitor p27
2.	Mitogen-Activated Protein Kinases
3.	Cyclins
4.	Phosphotransferases (Kinase)